Pharmaceutisch weekblad. Scientific edition最新文献_第9页

Animal models for testing anti-inflammatory drugs for treatment of bronchial hyperreactivity in asthma. 抗炎药物治疗哮喘支气管高反应性的实验动物模型。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-12-13 DOI: 10.1007/BF02015576

M J Linssen, O H Wilhelms, H Timmerman

{"title":"Animal models for testing anti-inflammatory drugs for treatment of bronchial hyperreactivity in asthma.","authors":"M J Linssen, O H Wilhelms, H Timmerman","doi":"10.1007/BF02015576","DOIUrl":"https://doi.org/10.1007/BF02015576","url":null,"abstract":"In the first part of this review the important role played by the bronchial hyperreactivity caused by chronic bronchopulmonary inflammation in asthma is described. Deliberately, more emphasis is placed on the role of pro-inflammatory eosinophils, alveolar macrophages, lymphocytes and platelets rather than on mast cells and neutrophils or the numerous mediators. The reason for this is that, on account of the large number of mediators and their multitude of functions and interactions in asthma, antagonism of a specific mediator will probably not be clinically relevant for optimally effective curative treatment of asthma. Inhibition of the infiltration and activation of pro-inflammatory cells is likely to be a more successful approach. In the second part, various animal models of bronchial hyperreactivity, which could be suitable for testing anti-asthmatic drugs, are discussed. Most animal models pay too little attention to chronic bronchopulmonary inflammation as the cause of bronchial hyperreactivity in asthma. In various models the bronchial hyperreactivity is provoked by a single mediator and this leads to selection of specific antagonists which are unlikely to be of clinical benefit. Rats appear to have certain advantages over guinea-pigs as experimental animals for bronchial hyperreactivity.","PeriodicalId":19804,"journal":{"name":"Pharmaceutisch weekblad. Scientific edition","volume":"13 6","pages":"225-37"},"PeriodicalIF":0.0,"publicationDate":"1991-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02015576","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12958115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Oxytocics for the prevention of post-partum haemorrhages. A review. 催产素用于预防产后出血。复习一下。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-12-13 DOI: 10.1007/BF02015577

P W Van Dongen, J Van Roosmalen, C N De Boer, J Van Rooij

引用次数: 12

In vitro and in vivo comparison of creams containing dithranol 0.5%. 含0.5%地萘醇乳膏的体内外比较。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18 DOI: 10.1007/BF01988877

J J Ros, Y G Van der Meer, D De Hoop, W J De Kort, P Van Andel

引用次数: 1

Abstracts of papers. Bi-annual scientific meeting of the Dutch Society of Hospital Pharmacists. Maastricht (The Netherlands), 13-14 September 1991. 论文摘要。荷兰医院药剂师协会两年一次的科学会议。马斯特里赫特(荷兰)，1991年9月13日至14日。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18

引用次数: 0

Abstracts of papers. Pharmacological meeting. Utrecht (The Netherlands), 6 November and 4 December 1991. 论文摘要。药理会议。乌得勒支(荷兰)，1991年11月6日和12月4日。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18

引用次数: 0

Abstracts of papers. Age and pharmacotherapy. 20th European Symposium on Clinical Pharmacy. Poznań (Poland), 23-26 October 1991. 论文摘要。年龄和药物治疗。第20届欧洲临床药学研讨会。波兹纳齐(波兰)，1991年10月23日至26日。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18

引用次数: 0

Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfamethomidine in humans. 磺胺嘧啶在人体内的药代动力学、n1 -葡萄糖醛酸化和n4 -乙酰化。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18 DOI: 10.1007/BF01988875

T B Vree, E W Beneken Kolmer, Y A Hekster

{"title":"Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfamethomidine in humans.","authors":"T B Vree, E W Beneken Kolmer, Y A Hekster","doi":"10.1007/BF01988875","DOIUrl":"https://doi.org/10.1007/BF01988875","url":null,"abstract":"Sulfamethomidine metabolism was studied in 6 volunteers. In humans, only N1-glucuronidation and N4-acetylation take place, leading to the final double conjugate N4-acetylsulfamethomidine N1-glucuronide. The N1-glucuronides were directly measured by high pressure liquid chromatography. Fast and slow acetylators show a similar half-life for sulfamethomidine (26 +/- 6 h) and its conjugates sulfamethomidine (26 +/- 6 h) and N4-acetylsulfamethomidine (36 +/- 16 h). Approximately 50-60% of the oral dose of sulfamethomidine is excreted in the urine, leaving 40-50% for excretion into bile and faeces. The main metabolite of sulfamethomidine is its N1-glucuronide, which accounts for 36 +/- 7% of the dose, followed by N4-acetylsulfamethomidine (16 +/- 8%). N1-glucuronidation results in a 75% decrease in protein binding of sulfamethomidine. N4-acetylsulfamethomidine and its N1-glucuronide showed the same high protein binding of 99%. The renal clearance of N4-acetylsulfamethomidine is 7.9 +/- 2.2 ml/min and approximately 20 times as high as that of the parent drug (0.46 +/- 0.16 ml/min). Total body clearance of sulfamethomidine is 4.5 +/- 0.9 ml/min and the volume of distribution in steady state 10.6 +/- 1.7 1. No measurable plasma concentrations of the N1-glucuronides from sulfamethomidine are found in plasma. This may be explained by renal glucuronidation after active tubular reabsorption.","PeriodicalId":19804,"journal":{"name":"Pharmaceutisch weekblad. Scientific edition","volume":"13 5","pages":"198-206"},"PeriodicalIF":0.0,"publicationDate":"1991-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF01988875","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12913446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Omeprazole. A pharmaco-epidemiological study of its use in a university hospital. 奥美拉唑。一所大学医院对其使用情况的药物流行病学研究。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18 DOI: 10.1007/BF01988878

D M Burger, Y A Hekster, W P Hopman, R Does

引用次数: 1

Controlling cancer chemotherapy-induced emesis. An update. 控制癌症化疗引起的呕吐。一个更新。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18 DOI: 10.1007/BF01988874

C Seynaeve, P H De Mulder, J Verweij, R J Gralla

{"title":"Controlling cancer chemotherapy-induced emesis. An update.","authors":"C Seynaeve, P H De Mulder, J Verweij, R J Gralla","doi":"10.1007/BF01988874","DOIUrl":"https://doi.org/10.1007/BF01988874","url":null,"abstract":"Cytotoxic chemotherapy can induce acute, delayed and anticipatory nausea and vomiting. The efficacy and toxicity data of the available anti-emetics and their role in chemotherapy-induced emesis are reviewed. Moreover, some pitfalls in the methodology of anti-emetic trials as well as factors known to affect the individual sensitivity of patients for the emetic challenge are illustrated. So far, high-dose metoclopramide (3-6 mg.kg-1.d-1) was the most effective single agent in the control of acute emesis. However, extrapyramidal reactions caused by its dopamine antagonism remained a major drawback. The addition of dexamethasone and/or lorazepam decreases the incidence of extrapyramidal reactions, and further improves anti-emetic control. In animals, serotonin type 3 receptor antagonists have demonstrated promising anti-emetic results against chemotherapy-induced and radiotherapy-induced emesis; the results of clinical studies are awaited. Delayed nausea and vomiting have not been studied as extensively. At present, the combination of metoclopramide and dexamethasone offers an optimal protection in approximately 50% of patients on cisplatin chemotherapy. Anticipatory nausea and emesis remain major problems, and an effective pharmacological treatment is lacking. Attempts to control this type of emesis focus on drugs with amnesic properties and on behaviour therapy.","PeriodicalId":19804,"journal":{"name":"Pharmaceutisch weekblad. Scientific edition","volume":"13 5","pages":"189-97"},"PeriodicalIF":0.0,"publicationDate":"1991-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF01988874","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12913447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Ofloxacin intravenous. Compatibility with other antibacterial agents. 氧氟沙星静脉。与其他抗菌剂的相容性。

Pharmaceutisch weekblad. Scientific edition Pub Date : 1991-10-18 DOI: 10.1007/BF01988876

R Janknegt, T Stratermans, J Cilissen, J J Lohman, P M Hooymans

引用次数: 0